Latest Europe News

Krakatoa Resources has kicked off its 2026 drilling campaign at the Zopkhito Project in Georgia, aiming to convert a significant foreign resource estimate into a JORC-compliant Mineral Resource Estimate while advancing early mine development studies.

Vista Group has landed a significant contract to transition Cineplexx’s European cinema circuit to its cloud-based Operational Excellence platform, covering 59 sites and over 400 screens across 11 countries.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

Australian Rare Earths (ASX: AR3) has announced a maiden Ore Reserve of 26 million tonnes at 920 ppm TREO for its Koppamurra Rare Earths Project, underpinned by a robust Pre-Feasibility Study delivering an A$858 million post-tax NPV and a rapid payback of less than one year.

SunRice reported a 4% rise in net profit after tax for FY26 to $73.3 million, maintaining an 8% EBITDA margin despite a 2.5% revenue decline. The company declared a record fully franked dividend of 70 cents per share but expects FY27 profit to fall amid a smaller Australian rice crop.

Corporate Travel Management (ASX:CTD) has pushed back its FY25 and 1HFY26 financial statements to August 2026 due to intertwined UK customer remediation, financing negotiations, and audit complexities, while signalling significant goodwill impairments across multiple regions.

EROAD Limited reported stable FY26 revenue of NZD 195 million amid a $134.7 million North American impairment, unveiling a strategic reset centred on ANZ growth and its expanding electronic Road User Charges platform.

European Metals Holdings reveals lithium chemical plant design improvements at Cinovec that could slash reagent and power costs by over US$54 million annually, potentially boosting the project’s pre-tax NPV beyond US$1.455 billion.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Elementos Limited has secured a key regulatory milestone as the Regional Government of Andalucía grants its Oropesa Tin Project Overriding Public Interest status, easing the path for critical water licensing and advancing permitting certainty.